A Phase 3, randomized, double-blind, placebo-controlled, parallelgroup, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis.

Project: Research

Project Details

Project Description


StatusActive
Effective start/end date14/02/2413/02/26

Keywords

  • Clinical trial
  • EFC17559